PL405451A1 - Prekursor radiofarmaceutyku i radiofarmaceutyk oparty na analogach dezacylogreliny, sposób ich wytwarzania oraz ich zastosowanie - Google Patents
Prekursor radiofarmaceutyku i radiofarmaceutyk oparty na analogach dezacylogreliny, sposób ich wytwarzania oraz ich zastosowanieInfo
- Publication number
- PL405451A1 PL405451A1 PL405451A PL40545113A PL405451A1 PL 405451 A1 PL405451 A1 PL 405451A1 PL 405451 A PL405451 A PL 405451A PL 40545113 A PL40545113 A PL 40545113A PL 405451 A1 PL405451 A1 PL 405451A1
- Authority
- PL
- Poland
- Prior art keywords
- ser
- radiopharmaceutical
- gln
- precursor
- leu
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title abstract 7
- 229940121896 radiopharmaceutical Drugs 0.000 title abstract 7
- 230000002799 radiopharmaceutical effect Effects 0.000 title abstract 7
- 239000002243 precursor Substances 0.000 title abstract 4
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 abstract 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229940044173 iodine-125 Drugs 0.000 abstract 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000000163 radioactive labelling Methods 0.000 abstract 1
- 208000011581 secondary neoplasm Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Prekursorami radiofarmaceutyków do znakowania radionuklidami terapeutycznymi i diagnostycznymi są analogi dezacylogreliny H-Gly-Ser-Ser-Tyr-Leu-OH (Tyr4-dezacylogrelina(1-5)), H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-OH (dezacylogrelina(1-10)) oraz H-Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-OH (dezacylogrelina(1-14)). Radiofarmaceutyk to prekursor wyznakowany nuklidem. Sposób wytwarzania radiofarmaceutyków polega na tym, że przeprowadza się reakcję radioznacznikowania jodem-123, jodem-125 lub jodem-131 roztworem Nal, gdzie I ma wyżej podane znaczenie, w borokrzemowej fiolce w buforze fosforanowym o odpowiednim pH (reszty tyrozylowe pH = 7-7,5, reszty histydylowe pH >= 9), prowadząc reakcję w temperaturze pokojowej, korzystnie przez 15 minut. Radiofarmaceutyk zawierający połączenie prekursora z radionuklidem stosuje się do wytwarzania leków i środków diagnostycznych w terapii wykrywania i/lub zahamowania wzrostu lub całkowitej eradykacji nowotworów pierwotnych i/lub wtórnych (przerzutów), i/lub komórek metastazujących wykazujących ekspresję receptora specyficznie rozpoznającego radiofarmaceutyk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40545113A PL233534B1 (pl) | 2013-09-26 | 2013-09-26 | Prekursor radiofarmaceutyku, radiofarmaceutyki oparte na analogach dezacylogreliny, oraz ich zastosowanie |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40545113A PL233534B1 (pl) | 2013-09-26 | 2013-09-26 | Prekursor radiofarmaceutyku, radiofarmaceutyki oparte na analogach dezacylogreliny, oraz ich zastosowanie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL405451A1 true PL405451A1 (pl) | 2015-03-30 |
| PL233534B1 PL233534B1 (pl) | 2019-10-31 |
Family
ID=52727682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL40545113A PL233534B1 (pl) | 2013-09-26 | 2013-09-26 | Prekursor radiofarmaceutyku, radiofarmaceutyki oparte na analogach dezacylogreliny, oraz ich zastosowanie |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL233534B1 (pl) |
-
2013
- 2013-09-26 PL PL40545113A patent/PL233534B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL233534B1 (pl) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krasnovskaya et al. | Recent advances in 64Cu/67Cu-based radiopharmaceuticals | |
| Tafreshi et al. | Development of targeted alpha particle therapy for solid tumors | |
| Lepareur et al. | Clinical advances and perspectives in targeted radionuclide therapy | |
| Sanad et al. | Radiodiagnosis of peptic ulcer with technetium-99 m-pantoprazole | |
| WO2015073746A3 (en) | 18f labeling of proteins using sortases | |
| Sharma et al. | Radiometals in imaging and therapy: highlighting two decades of research | |
| MX2018008168A (es) | Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia. | |
| EA202191691A1 (ru) | Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство | |
| MY188934A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| CN113354669B (zh) | 肿瘤诊疗一体化的硼携带剂、其制备方法和用途 | |
| PE20091723A1 (es) | Derivados de acido l-glutamico marcado con [18 f] y l-glutamina marcada con [18f] | |
| Hassan et al. | A review of recent advancements in Actinium‐225 labeled compounds and biomolecules for therapeutic purposes | |
| JP2017502946A5 (pl) | ||
| Gao et al. | The Different Strategies for the Radiolabeling of [211At]-Astatinated Radiopharmaceuticals | |
| Zhou et al. | Hydroxypyridinones as a very promising platform for targeted diagnostic and therapeutic radiopharmaceuticals | |
| Jiang et al. | 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma | |
| JP2015516457A (ja) | 放射性医薬品の製造用キット及び製造方法 | |
| PL405451A1 (pl) | Prekursor radiofarmaceutyku i radiofarmaceutyk oparty na analogach dezacylogreliny, sposób ich wytwarzania oraz ich zastosowanie | |
| CN103951668A (zh) | 叶酸衍生物的正电子核素标记物及其应用 | |
| ES2689818T3 (es) | Tratamiento de artritis inmunitaria, inflamatoria y degenerativa con estaño-117m | |
| Zhang et al. | Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy | |
| Zhu et al. | Synthesis and biological evaluation of novel 99mTc-oxo and 99mTc-nitrido complexes with phenylalanine dithiocarbamate for tumor imaging | |
| WO2015143019A3 (en) | Gaseous f-18 technologies | |
| Khalid et al. | Evaluation of carrier added and no carrier added 90 Y-EDTMP as bone seeking therapeutic radiopharmaceutical. | |
| Novy et al. | The effect of chelator type on in vitro receptor binding and stability in 177Lu‐labeled cetuximab and panitumumab |